Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.

Eitemau Tebyg

• Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
  gan: Kevin McLaughlin PharmD, BCPS, et al.
  Cyhoeddwyd: (2019-09-01)
• The use of activated partial thromboplastin time versus antifactor Xa assay in monitoring continuous unfractionated heparin infusion therapy in obstetric intensive care unit
  gan: Hany V. Zaki, et al.
  Cyhoeddwyd: (2019-02-01)
• PARTIAL THROMBOPLASTIN TIME CHANGES IN ASTHMA
  gan: A MIRALAEI, et al.
  Cyhoeddwyd: (2003-03-01)
• A Recurrent Neural Network Model for Predicting Activated Partial Thromboplastin Time After Treatment With Heparin: Retrospective Study
  gan: Sebastian Daniel Boie, et al.
  Cyhoeddwyd: (2022-10-01)
• An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
  gan: Yuan Teng, et al.
  Cyhoeddwyd: (2022-06-01)